Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the
Company”), a biotechnology company focused on discovering and
developing transformative therapeutics for patients, today
announces the Company’s Chief Scientific Officer, Michael Newman,
Ph.D., has been named chair for two of the three days of the 4th
STING & TLR-Targeting Therapies Summit to be held in Boston on
May 9-11, where he will also be a featured speaker.
Dr. Newman’s first talk, “Breaking the Toxicity Barrier: Tumor
Eradication in Pre-Clinical Models by Systemic Administration of a
Multi-TLR, NOD and STING Agonist,” which features the Company’s
cancer research on its Decoy platform will be held on May 10th at
1:30PM. The research discussed is also reflective of the recently
presented poster during the American Association for Cancer
Research, presented April 18th.
Dr. Newman’s second talk, “Pre-Clinical Anti-HBV Activity with a
Passively Targeted, Multi-TLR, NOD and STING Agonist,” which
features the Company’s infectious disease research on its Decoy
platform will be held on May 11th at 2:30PM.
Jeffrey Meckler, Indaptus’s CEO commented, “We are thrilled for
Dr. Newman that he has been recognized for his important work in
both the cancer and infectious disease fields with the honor of
chairing and giving two presentations at the summit. We look
forward to his presentations demonstrating our approach to
utilizing killed decoy bacteria to induce the priming of both
innate and adaptive anti-tumor immunity, as well as our ability to
use the platform to produce broad and significant inhibition of
chronic hepatitis B virus infection in a pre-clinical model at such
a prestigious event. The STING & TLR-Targeting Therapies Summit
is an important venue in which to exchange scientific insight among
the leaders in the innate and adaptive immune target-mediated
activation space and we anticipate lively and informative
discussion around both individual scientific progress and the
industry as a whole.”
The 4th STING & TLR Targeting Therapies Summit will bring
together in person, for the first time, 100+ of the biggest players
in the innate targeting therapies space from large pharma, biotech,
and academia. The agenda is designed to explore the plethora of
STING and TLR agonists in development, review clinical trial data,
learn from high-profile failures, assess delivery approaches, and
discuss strategies to optimize clinical trials and accelerate
innate agonist pipelines.
Committed to providing innovative scientific insights, the
program includes new sessions to broaden participants’
understanding of PRR activation, expanding beyond oncology and
looking at both agonists and antagonists to treat infectious
diseases and address inflammation. Deep diving into the role that
the microbiome plays in innate immune regulation to provide a more
holistic overview of how the STING and TLR activation are
regulated. The event will be held at the Hilton Boston Back Bay in
Boston.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company’s novel approach
is based on the hypothesis that efficient activation of both innate
and adaptive immune cells and pathways and associated anti-tumor
and anti-viral immune responses will require a multi-targeted
package of immune system-activating signals that can be
administered safely intravenously (i.v.). Indaptus’ patented
technology is composed of single strains of attenuated and killed,
non-pathogenic, Gram-negative bacteria producing a multiple
Toll-like receptor (TLR) agonist Decoy platform. The products are
designed to have reduced i.v. toxicity, but largely uncompromised
ability to prime or activate many of the cells and pathways of
innate and adaptive immunity.
Decoy products represent an antigen-agnostic
technology that have produced single-agent activity against
metastatic pancreatic and orthotopic colorectal carcinomas, single
agent eradication of established antigen-expressing breast
carcinoma, as well as combination-mediated eradication of
established hepatocellular carcinomas and non-Hodgkin’s lymphomas
in standard pre-clinical models, including syngeneic mouse tumors
and human tumor xenografts. In pre-clinical studies tumor
eradication was observed with Decoy products in combination with
anti-PD-1 checkpoint therapy, low-dose chemotherapy, a
non-steroidal anti-inflammatory drug, or an approved, targeted
antibody. Combination-based tumor eradication in pre-clinical
models produced innate and adaptive immunological memory, involved
activation of both innate and adaptive immune cells, and was
associated with induction of innate and adaptive immune pathways in
tumors after only one i.v. dose of Decoy product, with associated
“cold” to “hot” tumor inflammation signature transition.
IND-enabling, nonclinical toxicology studies
demonstrated safe i.v. administration without sustained induction
of hallmark biomarkers of cytokine release syndromes, possibly due
to passive targeting to liver, spleen, and tumor, followed by rapid
elimination of the product. Indaptus’ Decoy products have also
produced significant single agent activity against chronic
hepatitis B virus (HBV) and chronic human immunodeficiency virus
(HIV) infections in pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking
statements with the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management’s
expectations, beliefs and intentions regarding, among other things,
our expectations and plans regarding the Phase 1 clinical trial of
Decoy20, including the timing and design thereof; the plans and
objectives of management for future operations; our research and
development activities; and our beliefs regarding the efficacy of
our product candidates and the Decoy platform. Forward-looking
statements can be identified by the use of forward-looking words
such as “believe”, “expect”, “intend”, “plan”, “may”, “should”,
“could”, “might”, “seek”, “target”, “will”, “project”, “forecast”,
“continue” or “anticipate” or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. Because
forward-looking statements relate to matters that have not yet
occurred, these statements are inherently subject to risks and
uncertainties that could cause our actual results to differ
materially from any future results expressed or implied by the
forward-looking statements. Many factors could cause actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements, including, but
not limited to the following: our limited operating history; the
need for, and our ability to raise, additional capital given our
lack of current cash flow; our clinical and preclinical
development, which involves a lengthy and expensive process with an
uncertain outcome; our incurrence of significant research and
development expenses and other operating expenses, which may make
it difficult for us to attain profitability; our pursuit of a
limited number of research programs, product candidates and
specific indications and failure to capitalize on product
candidates or indications that may be more profitable or have a
greater likelihood of success; our ability to obtain and maintain
regulatory approval of any product candidate; the market acceptance
of our product candidates; our reliance on third parties to conduct
our preclinical studies and clinical trials and perform other
tasks; our reliance on third parties for the manufacture of our
product candidates during clinical development; our ability to
successfully commercialize Decoy20 or any future product
candidates; our ability to obtain or maintain coverage and adequate
reimbursement for our products; the impact of legislation and
healthcare reform measures on our ability to obtain marketing
approval for and commercialize Decoy20 and any future product
candidates; product candidates of our competitors that may be
approved faster, marketed more effectively, and better tolerated
than our product candidates; our ability to adequately protect our
proprietary or licensed technology in the marketplace; the impact
of, and costs of complying with healthcare laws and regulations,
and our failure to comply with such laws and regulations;
information technology system failures, cyberattacks or
deficiencies in our cybersecurity; and unfavorable global economic
conditions. These and other important factors discussed under the
caption “Risk Factors” included in our most recent Annual Report on
Form 10-K filed with the SEC on March 17, 2023, and our other
filings with the SEC, could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. All forward-looking statements speak
only as of the date of this press release and are expressly
qualified in their entirety by the cautionary statements included
in this press release. We undertake no obligation to update or
revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IRLouie Tomalouie@coreir.com
CORE IRJules Abraham (media)917-885-7378julesa@coreir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Apr 2024 to May 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From May 2023 to May 2024